FDA Removes Clinical Hold from Aastrom Phase II IMPACT-DCM Clinical Trial

News   Jun 23, 2009

 
FDA Removes Clinical Hold from Aastrom Phase II IMPACT-DCM Clinical Trial
 
 
 

RELATED ARTICLES

“Nanokicking” Technology Enables Breakthrough in the Culture of 3D Mineralised Bone Tissue

News

Researchers have grown 3D samples of mineralised bone from human mesenchymal stem cells for the first time without typical osteoinductive media.

READ MORE

Cancer Cells’ Energy Source Blocked by Natural Compound

News

Researchers have not only untangled an unusual wiring system that cancer cells use for carbohydrate metabolism, but also identified a natural compound that appears to selectively shut down this system in laboratory studies.

READ MORE

How do Poison Frogs Protect Themselves Against Their Own Neurotoxin?

News

Scientists are a step closer to resolving a related head-scratcher, how do these frogs keep from poisoning themselves?

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Cell Science

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE